Tirzepatide response after eight weeks

People who lost at least 5% of body weight by week eight on tirzepatide went on to lose more weight by week 72 than those below that early threshold. Yet the later-response group also achieved meaningful average losses. In SURMOUNT-1, without type 2 diabetes, week-72 estimates were 23.3% for early responders and 14.6% for nonearly responders. In SURMOUNT-2, with type 2 diabetes, they were 20.0% and 10.8%^[1]. The analysis describes an association after treatment began. It does not validate an eight-week rule for stopping or changing treatment.

How the groups were defined

This was a post hoc, or unplanned after the main trial design, analysis of two randomized phase 3 trials. It included 1,775 tirzepatide-treated participants from SURMOUNT-1 and 609 from SURMOUNT-2. Researchers grouped them by weight change at week eight: at least 5% loss counted as an early response, while less than 5% counted as nonearly^[2]. Placebo recipients were not part of this comparison.

Week eight was chosen because every included participant had completed four weeks on 2.5 mg and four weeks on 5 mg, with the next dose increase scheduled. Overall, 56.6% met the early-response definition. The proportion was 62.1% in SURMOUNT-1 but 40.6% in SURMOUNT-2^[2]. Those proportions are specific to the trial schedules and included populations. They are not a probability estimate for every patient starting tirzepatide.

The 72-week results

The curves continued to separate after week eight. In SURMOUNT-1, early responders moved from an estimated 7.9% loss at week eight to 23.3% at week 72. Nonearly responders moved from 3.1% to 14.6%. In SURMOUNT-2, the corresponding path was 7.1% to 20.0% for early responders and 2.5% to 10.8% for nonearly responders^[2]. Every randomized dose showed the same directional pattern.

The difference also appeared at higher weight-loss thresholds. In SURMOUNT-1, 63.4% of early responders reached at least 20% loss by week 72, compared with 28.1% of nonearly responders. In SURMOUNT-2, those figures were 52.2% and 12.2%^[2]. These are descriptive subgroup results based on response measured during the same treatment course. They do not show that crossing 5% at week eight caused the later outcome.

Dose-specific estimates pointed in the same direction. In SURMOUNT-1, the week-72 difference between early and nonearly responders was present in every randomized arm. The 5 mg averages were 18.9% and 10.6%, while the 15 mg averages were 25.9% and 18.1%^[2]. These numbers describe trial groups under a fixed escalation schedule. They are not instructions for choosing a dose. The tirzepatide dosing evidence section explains how study schedules differ from prescribing decisions. Regulatory context also varies, as shown on the US tirzepatide page and UK tirzepatide page. A prescriber has to consider tolerability and the approved product information rather than selecting a dose from subgroup averages.

Cardiometabolic measures generally improved in both groups. Among SURMOUNT-2 participants, HbA1c fell by an estimated 2.5 percentage points in early responders and 2.0 points in nonearly responders. Normoglycaemia, defined in the paper as HbA1c below 5.7%, was reached by 69.7% and 41.2%, respectively^[2]. Glycaemic improvement was therefore not confined to people who crossed the early weight threshold.

Tolerability did not create a simple predictor

Nausea was reported during the first eight weeks by 19.6% of SURMOUNT-1 early responders and 14.1% of nonearly responders. In SURMOUNT-2, the figures were 11.7% and 8.3%. Most participants in every subgroup reported no nausea, vomiting or diarrhoea during that period, and gastrointestinal-event patterns generally decreased over time^[2]. The authors concluded that gastrointestinal symptoms were not a useful stand-alone predictor of how much weight a participant would lose.

Early responders and nonearly responders were not interchangeable groups. Early responders were more often female and White, and their baseline HbA1c was lower. Only participants still on treatment with both baseline and week-eight weight data entered the analysis^[2]. Discontinuation by response group was therefore unavailable. Differences in diet, education, income or exercise could also contribute, even though dose assignment in the original trials was randomized.

What we don't yet know

The comparisons were not prespecified, were not adjusted for multiple testing, and were not powered to establish differences between response groups. The authors describe them as hypothesis-generating^[2]. The findings also do not tell us whether changing a dose or ending treatment at week eight improves long-term outcomes. That would require a trial that assigns different management strategies based on early response.

The useful message is modest. Early weight change carries information about the likely trajectory, but falling short of 5% at week eight did not mean treatment had failed. The nonearly groups still lost an average of 10.8% to 14.6% by week 72. Readers can review the broader tirzepatide evidence summary and tirzepatide safety section. Decisions about dose escalation or continued treatment belong with the prescribing clinician, not an isolated early percentage.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.